Research Of RT-PCR For Measurement Of Bcr/abl Fusion Gene MRNA Transcripts And The Value Of Application On CML Clinical Treatment

Chronic myeloid leukemia (CML) is a clonal neoplastic disorder of hematopoietic stem cell, which characterized, produces the bcr/abl fusion gene. The bcr/abl gene encodes a chimeric protein (p210bcr/abl)with elevated tyrosine kinase activity, which plays an important role in the pathogenesis of the disease, we developed and evaluated a rapid and reliable RT-PCR technology for detection of bcr/abl transcrips in CML patients at diagnosis, during therapy and after bone marrow transplant (BMT). Methods: The primers were designed to amplify the most frequent bcr/abl transcripts not noly including b3a2 but also b2a2 transcripts.we choose k562 cell as sample and established a RT-PCR methed. We also detected 20 normal healthy individual, and no bcr/abl transcripts in their blood. It is a sensitivity, specificity, and reliability methed to detected bcr/abl transcripts in CML. we detected the bcr/abl positive ratio in 46 peripheral blood (PB) samples (26 samples at chronic phase and 20 samples at accelerated phase and blast crisis phase) from 30 CML patients, 10 samples in complete remission after therapy and 4 samples at post-BMT patient were also monitored with RT-PCR. Results: BY RT-PCR, one k562 cell in 105 cells from healthy donors can be detected. The bcr/abl transcrips positive ration were 92.3% at chronic phase, The bcr/abl mRNA positive ration were...